



## Metabolomic analyses reveal new stage-specific features of COVID-19

Hongling Jia<sup>1,2,16</sup>, Chaowu Liu<sup>3,16</sup>, Dantong Li<sup>4,16</sup>, Qingsheng Huang<sup>5,16</sup>, Dong Liu<sup>6,16</sup>, Ying Zhang<sup>1,16</sup>, Chang Ye<sup>5</sup>, Di Zhou<sup>7</sup>, Yang Wang<sup>7</sup>, Yanlian Tan<sup>2</sup>, Kuibiao Li<sup>1</sup>, Fangqin Lin<sup>5</sup>, Haiqing Zhang<sup>8</sup>, Jingchao Lin<sup>7</sup>, Yang Xu<sup>1</sup>, Jingwen Liu<sup>1</sup>, Qing Zeng<sup>1</sup>, Jian Hong<sup>9</sup>, Guobing Chen<sup>10</sup>, Hao Zhang<sup>11</sup>, Lingling Zheng<sup>5</sup>, Xilong Deng<sup>12</sup>, Changwen Ke<sup>13</sup>, Yunfei Gao<sup>14,15,17</sup>, Jun Fan <sup>02,17</sup>, Biao Di<sup>1,17</sup> and Huiying Liang<sup>4,17</sup>

<sup>1</sup>Guangzhou Center for Disease Control and Prevention, Guangzhou, China. <sup>2</sup>Dept of Medical Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou, China. <sup>3</sup>Guangdong Institute of Microbiology, Guangdong Academy of Sciences, State Key Laboratory of Applied Microbiology Southern China, Guangzhou, China. <sup>4</sup>Clinical Data Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical Sciences, Guangzhou, China. <sup>5</sup>Elip Data and Machine Learning Laboratory, Chongqing University of Technology, Chongqing, China. <sup>7</sup>Metabo-Profile Biotechnology (Shanghai) Co. Ltd, Shanghai, China. <sup>8</sup>Dept of Occupational and Environmental Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. <sup>9</sup>Dept of Pathophysiology, School of Medicine, Jinan University, Guangzhou, China. <sup>10</sup>Institute of Geriatric Immunology, Dept of Microbiology and Immunology, School of Medicine, Dept of Neurology, Affiliated Huaqiao Hospital, Jinan University, Guangzhou, China. <sup>11</sup>Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, China. <sup>13</sup>Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China. <sup>14</sup>Zhuhai Precision Medical Center, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Jinan University, Zhuhai, China. <sup>15</sup>The Biomedical Translational Research Institute, Jinan University Faculty of Medical Science, Jinan University, China, China. <sup>16</sup>These authors contributed equally to this study. <sup>17</sup>Yunfei Gao, Jun Fan, Biao Di and Huiying Liang are joint lead authors.

Corresponding author: Huiying Liang (lianghuiying@hotmail.com)



Shareable abstract (@ERSpublications)

This cross-sectional metabolomics study proved that serum metabolite profiles are significantly different in different COVID-19 stages. The TCA and urea pathways may participate in pathological processes associated with COVID-19 progression. https://bit.ly/3hyB9RK

Cite this article as: Jia H, Liu C, Li D, et al. Metabolomic analyses reveal new stage-specific features of COVID-19. Eur Respir J 2022; 59: 2100284 [DOI: 10.1183/13993003.00284-2021].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

This article has an editorial commentary: https://doi.org/10.1183/13993003.02417-2021

Received: 2 Oct 2020 Accepted: 28 June 2021





## Abstract

The current pandemic of coronavirus disease 2019 (COVID-19) has affected >160 million individuals to date, and has caused millions of deaths worldwide, at least in part due to the unclarified pathophysiology of this disease. Identifying the underlying molecular mechanisms of COVID-19 is critical to overcome this pandemic. Metabolites mirror the disease progression of an individual and can provide extensive insights into their pathophysiological significance at each stage of disease. We provide a comprehensive view of metabolic characterisation of sera from COVID-19 patients at all stages using untargeted and targeted metabolomic analysis. As compared with the healthy controls, we observed different alteration patterns of circulating metabolites from the mild, severe and recovery stages, in both the discovery cohort and the validation cohort, which suggests that metabolic reprogramming of glucose metabolism and the urea cycle are potential pathological mechanisms for COVID-19 progression. Our findings suggest that targeting glucose metabolism and the urea cycle may be a viable approach to fight COVID-19 at various stages along the disease course.